Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer


General Information

Age Group




Protocol Number


Background Information

The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.

Offered At

Inova Fairfax Hospital
3300 Gallows Road
Fairfax, VA 22031

Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates (MAGOPSA)
8081 Innovation Park Drive
Fairfax, VA 22031

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital

Inova Loudoun Hospital
44045 Riverside Pkwy
Leesburg, VA 20176

Eligibility Information

  • Confirmed cervical cancer.
  • Must have adequate organ function.

Ineligibility Information

  • Subject is pregnant.
  • Recurrent cervical cancer.
  • Distant metastases.
  • Malignancy within the last 5 years; basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy is permissable.
  • Subject has had prior radiation, chemotherapy, targeted therapy, or investigational therapy for cervical cancer.
  • Subject has a immunodeficiency.
  • Known history of HIV, Hepatitis B, Hepatitis C, TB, or inflammatory bowel disease.
  • Hypersensitivity to pembrolizumab or similar drugs.
  • Subject has an active autoimmune disease in the past 2 years.
  • Known history of non-infectious pneumonitis.
  • Subject has an active infection.
  • Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases are permissible. Talk to Study Contact for specifics.

Additional information can be found at